The Filing Desk

Evolus vs Rigel Pharmaceuticals

Evolus EOLS · Rigel Pharmaceuticals RIGL · Pharmaceuticals

Evolus reported revenue of $297 million in fiscal 2025, about the same as Rigel Pharmaceuticals' $294 million in fiscal 2025. Evolus' revenue grew 11.6% in its latest year, and Rigel Pharmaceuticals' grew 64.2%. Evolus had an operating margin of -11.0%, against 42.6% at Rigel Pharmaceuticals.

Side by side

EvolusRigel Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$297M$294M
Revenue growth11.6%64.2%
Revenue growth a year, last 5 years39.4%22.1%
Gross margin66.3%93.3%
Operating margin−11.0%42.6%
Net margin−17.4%124.7%
Free cash flow−$46M—
Free cash flow margin−15.4%—
Return on capital−47.2%91.3%
Net debt to EBITDA—−0.8x
Dividends and buybacks$0M$0M
Change in diluted share count4.0%6.5%
Last close$6.96$44.46
P/E at the last close—2.8×
Insider trades, last 12 months——
Piotroski F-score2 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
EvolusRigel Pharmaceuticals
Operating margin
Percent of revenue
EvolusRigel Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EvolusRigel Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Evolus and Rigel Pharmaceuticals pages.